| Name | Title | Contact Details |
|---|
Agenixs creates change in the world by elevating people to healthier, longer, and more fulfilling lives, empowering each on their own journey of changing the world.
Genetic Technologies, Inc. is an independent, full service and multi-accredited DNA forensic science company focusing primarily on the testing and evaluation of forensic evidence as it relates to human identification. Established in 1998, Genetic Technologies, Inc. serves a rapidly growing nationwide and worldwide customer base of private citizens, investigators, law enforcement agencies, public defenders, criminal defense attorneys, and prosecutors. We offer our clients access to a broad range of forensic biology technologies—specializing in DNA analysis, (Autosomal and Y-STRs), touch DNA (Low Copy Analysis), Crime Scene Investigation (CSI), serology, and expert witness & consulting services for civil investigations / criminal prosecution & defense. Our forensic division has played a pivotal role in a hundreds of high profile criminal cases with our civil and relatedness divisions assisting clients in thousands of immigration / relatedness DNA tests including a wide spectrum of infidelity scenarios. Our seasoned staff of expert scientists utilizes the most advanced methodologies available to detect and test DNA from many sources. We offer fast, accurate and personalized service for each of our customers, including consulting and expert witness services in conjunction with forensic testing. Genetic Technologies, Inc. is a leader in the Forensic Science and Human Identification Industry and provides specialized software to the eDNA Consortium. eDNA is a software developed by Genetic Technologies, Inc. which is used by many facilities in the Human Identification Industry.
Broen Memorial Home is a Fergus Falls, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
Doctors Imaging Group provides coverage at the Diagnostic Imaging Center, North Florida Regional Medical Center and our satellite offices at West, East, and Palatka locations. At each of these centers our goal is two-fold.